arrow
H

Hans Martin

University of Montana
H指数:48
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Behavioral responses of terrestrial mammals to COVID-19 lockdowns
Science
IF45.8
2023-01-010
OAAI
Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
LEUKEMIA
IF13.4
2022-12-226
PRE
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
2021-07-0823
OAAI
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
2021-01-0714
OAAI
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE
LEUKEMIA
IF13.4
2020-07-2137
PREAI
Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation
2019-05-0146
OAAI
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
LEUKEMIA
IF13.4
2018-06-293
PRE
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
2017-05-2640
OAAI
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

德语骨髓瘤多中心组 (GMMG) 试验复发的基本原理和设计: 一项随机,开放,多中心III期试验,比较来那度胺/地塞米松与来那度胺/地塞米松联合后续自体干细胞移植和来那度胺维持治疗复发性多发性骨髓瘤

2016-04-257
OAAI
Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
2013-08-30102
OAAI